| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Medical Science Division, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 [H. Z., Z-S. C., M. G. B., G. D. K.], and Department of Biology, University of Pennsylvania, Philadelphia, Pennsylvania 19104 [P. A. R.]
We have recently determined that human multidrug resistance protein (MRP) 3, which confers resistance to certain natural product agents and methotrexate (MTX), is competent in the MgATP-energized transport of MTX and the monoanionic bile constituent glycocholate as well as several glutathione and glucuronate conjugates. Of these capabilities, the facility of MRP3 in conferring resistance to and mediating the transport of MTX is of particular interest because it raises the possibility that this pump is a component of the previously described cellular efflux system for this antimetabolite. However, if this is to be the case, a critical property of cellular MTX efflux that must be addressed is its ability to mediate the export of MTX but not that of its intracellular polyglutamylated derivatives. Here we examine the role of MRP3 in these and related processes by determining the selectivity of this transporter for MTX, MTX polyglutamates, and physiological folates. In so doing, we show that MRP3 is not only active in the transport of MTX but is also active in the transport the physiological folates folic acid (FA) and N5-formyltetrahydrofolic acid (leucovorin) and that polyglutamylation of MTX abolishes transport. Both FA and leucovorin are subject to high-capacity (Vmax(FA), 1.71 ± 0.05 nmol/mg/min; Vmax(leucovorin), 3.63 ± 1.20 nmol/mg/min), low-affinity (Km(FA), 1.96 ± 0.13 mM; Km(leucovorin), 1.74 ± 0.65 mM) transport by MRP3. Addition of a single glutamyl residue to MTX is sufficient to diminish transport by >95%. We also show that polyglutamylation similarly affects the capacity of MRP1 to transport MTX and that physiological folates are also subject to MgATP-stimulated transport by MRP1. On the basis of the capacity to transport MTX but not MTX-Glu2, it is concluded that MRP3 and MRP1 represent components of the previously described cellular efflux system for MTX. The capacity of MRP3 to transport folates indicates that it may reduce intracellular levels of these compounds and thereby indirectly influence antifolate cytotoxicity, and it also implies that this pump may play a role in the response to chemotherapeutic regimens in which leucovorin is a component.
This article has been cited by other articles:
![]() |
S. Dahlstrom, M. I. Veiga, A. Martensson, A. Bjorkman, and J. P. Gil Polymorphism in PfMRP1 (Plasmodium falciparum Multidrug Resistance Protein 1) Amino Acid 1466 Associated with Resistance to Sulfadoxine-Pyrimethamine Treatment Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2553 - 2556. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Raichaudhuri, M. Peng, V. Naponelli, S. Chen, R. Sanchez-Fernandez, H. Gu, J. F. Gregory III, A. D. Hanson, and P. A. Rea Plant Vacuolar ATP-binding Cassette Transporters That Translocate Folates and Antifolates in Vitro and Contribute to Antifolate Tolerance in Vivo J. Biol. Chem., March 27, 2009; 284(13): 8449 - 8460. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kitamura, M. Hirouchi, H. Kusuhara, J. D. Schuetz, and Y. Sugiyama Increasing Systemic Exposure of Methotrexate by Active Efflux Mediated by Multidrug Resistance-Associated Protein 3 (Mrp3/Abcc3) J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 465 - 473. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Ifergan, G. Jansen, and Y. G. Assaraf The Reduced Folate Carrier (RFC) Is Cytotoxic to Cells under Conditions of Severe Folate Deprivation: RFC AS A DOUBLE EDGED SWORD IN FOLATE HOMEOSTASIS J. Biol. Chem., July 25, 2008; 283(30): 20687 - 20695. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Matsushima, K. Maeda, H. Hayashi, Y. Debori, A. H. Schinkel, J. D. Schuetz, H. Kusuhara, and Y. Sugiyama Involvement of Multiple Efflux Transporters in Hepatic Disposition of Fexofenadine Mol. Pharmacol., May 1, 2008; 73(5): 1474 - 1483. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Hider, I. N. Bruce, and W. Thomson The pharmacogenetics of methotrexate Rheumatology, October 1, 2007; 46(10): 1520 - 1524. [Abstract] [Full Text] [PDF] |
||||
![]() |
S L Hider, A Owen, R Hartkoorn, S Khoo, D Back, A J Silman, and I N Bruce Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug Ann Rheum Dis, October 1, 2006; 65(10): 1390 - 1393. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Deeley, C. Westlake, and S. P. C. Cole Transmembrane Transport of Endo- and Xenobiotics by Mammalian ATP-Binding Cassette Multidrug Resistance Proteins. Physiol Rev, July 1, 2006; 86(3): 849 - 899. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. D. Cole, R. A. Drachtman, A. K. Smith, S. Cate, R. A. Larson, D. S. Hawkins, J. Holcenberg, K. Kelly, and B. A. Kamen Phase II Trial of Oral Aminopterin for Adults and Children with Refractory Acute Leukemia Clin. Cancer Res., November 15, 2005; 11(22): 8089 - 8096. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bedhomme, M. Hoffmann, E. A. McCarthy, B. Gambonnet, R. G. Moran, F. Rebeille, and S. Ravanel Folate Metabolism in Plants: AN ARABIDOPSIS HOMOLOG OF THE MAMMALIAN MITOCHONDRIAL FOLATE TRANSPORTER MEDIATES FOLATE IMPORT INTO CHLOROPLASTS J. Biol. Chem., October 14, 2005; 280(41): 34823 - 34831. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liu, H. Peng, and J.-T. Zhang Expression Profiling of ABC Transporters in a Drug-Resistant Breast Cancer Cell Line Using AmpArray Mol. Pharmacol., August 1, 2005; 68(2): 430 - 438. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Flaherty, G. Giaever, J. Kumm, M. I. Jordan, and A. P. Arkin A latent variable model for chemogenomic profiling Bioinformatics, August 1, 2005; 21(15): 3286 - 3293. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Belinsky, P. A. Dawson, I. Shchaveleva, L. J. Bain, R. Wang, V. Ling, Z.-S. Chen, A. Grinberg, H. Westphal, A. Klein-Szanto, et al. Analysis of the In Vivo Functions of Mrp3 Mol. Pharmacol., July 1, 2005; 68(1): 160 - 168. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Wielinga, J. H. Hooijberg, S. Gunnarsdottir, I. Kathmann, G. Reid, N. Zelcer, K. van der Born, M. de Haas, I. van der Heijden, G. Kaspers, et al. The Human Multidrug Resistance Protein MRP5 Transports Folates and Can Mediate Cellular Resistance against Antifolates Cancer Res., May 15, 2005; 65(10): 4425 - 4430. [Abstract] [Full Text] [PDF] |
||||
![]() |
J Wolf, T Stranzl, M Filipits, G Pohl, R Pirker, B Leeb, and J S Smolen Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis Ann Rheum Dis, April 1, 2005; 64(4): 564 - 568. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Filipits, G. Pohl, M. Rudas, O. Dietze, S. Lax, R. Grill, R. Pirker, C. C. Zielinski, H. Hausmaninger, E. Kubista, et al. Clinical Role of Multidrug Resistance Protein 1 Expression in Chemotherapy Resistance in Early-Stage Breast Cancer: The Austrian Breast and Colorectal Cancer Study Group J. Clin. Oncol., February 20, 2005; 23(6): 1161 - 1168. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Liu, Y. Ge, D. C. Cabelof, A. Aboukameel, A. R. Heydari, R. Mohammad, and L. H. Matherly Structure and Regulation of the Murine Reduced Folate Carrier Gene: IDENTIFICATION OF FOUR NONCODING EXONS AND PROMOTERS AND REGULATION BY DIETARY FOLATES J. Biol. Chem., February 18, 2005; 280(7): 5588 - 5597. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-S. Chen, Y. Guo, M. G. Belinsky, E. Kotova, and G. D. Kruh Transport of Bile Acids, Sulfated Steroids, Estradiol 17-{beta}-D-Glucuronide, and Leukotriene C4 by Human Multidrug Resistance Protein 8 (ABCC11) Mol. Pharmacol., February 1, 2005; 67(2): 545 - 557. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Shoji, H. Suzuki, H. Kusuhara, Y. Watanabe, S. Sakamoto, and Y. Sugiyama ATP-dependent transport of organic anions into isolated basolateral membrane vesicles from rat intestine Am J Physiol Gastrointest Liver Physiol, October 1, 2004; 287(4): G749 - G756. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Breedveld, N. Zelcer, D. Pluim, O. Sonmezer, M. M. Tibben, J. H. Beijnen, A. H. Schinkel, O. van Tellingen, P. Borst, and J. H. M. Schellens Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles: Potential Role for Breast Cancer Resistance Protein in Clinical Drug-Drug Interactions Cancer Res., August 15, 2004; 64(16): 5804 - 5811. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Ifergan, A. Shafran, G. Jansen, J. H. Hooijberg, G. L. Scheffer, and Y. G. Assaraf Folate Deprivation Results in the Loss of Breast Cancer Resistance Protein (BCRP/ABCG2) Expression: A ROLE FOR BCRP IN CELLULAR FOLATE HOMEOSTASIS J. Biol. Chem., June 11, 2004; 279(24): 25527 - 25534. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Volk and E. Schneider Wild-Type Breast Cancer Resistance Protein (BCRP/ABCG2) is a Methotrexate Polyglutamate Transporter Cancer Res., September 1, 2003; 63(17): 5538 - 5543. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Stark, L. Rothem, G. Jansen, G. L. Scheffer, I. D. Goldman, and Y. G. Assaraf Antifolate Resistance Associated with Loss of MRP1 Expression and Function in Chinese Hamster Ovary Cells with Markedly Impaired Export of Folate and Cholate Mol. Pharmacol., August 1, 2003; 64(2): 220 - 227. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-S. Chen, R. W. Robey, M. G. Belinsky, I. Shchaveleva, X.-Q. Ren, Y. Sugimoto, D. D. Ross, S. E. Bates, and G. D. Kruh Transport of Methotrexate, Methotrexate Polyglutamates, and 17{beta}-Estradiol 17-({beta}-D-glucuronide) by ABCG2: Effects of Acquired Mutations at R482 on Methotrexate Transport Cancer Res., July 15, 2003; 63(14): 4048 - 4054. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Zelcer, M. T. Huisman, G. Reid, P. Wielinga, P. Breedveld, A. Kuil, P. Knipscheer, J. H. M. Schellens, A. H. Schinkel, and P. Borst Evidence for Two Interacting Ligand Binding Sites in Human Multidrug Resistance Protein 2 (ATP Binding Cassette C2) J. Biol. Chem., June 20, 2003; 278(26): 23538 - 23544. [Abstract] [Full Text] [PDF] |
||||
![]() |
S L Hider, C Morgan, E Bell, I N Bruce, P Ranganathan, and H L McLeod Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with RA? Ann Rheum Dis, June 1, 2003; 62(6): 591 - 591. [Full Text] [PDF] |
||||
![]() |
Y. G. Assaraf, L. Rothem, J. H. Hooijberg, M. Stark, I. Ifergan, I. Kathmann, B. A. C. Dijkmans, G. J. Peters, and G. Jansen Loss of Multidrug Resistance Protein 1 Expression and Folate Efflux Activity Results in a Highly Concentrative Folate Transport in Human Leukemia Cells J. Biol. Chem., February 21, 2003; 278(9): 6680 - 6686. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-S. Chen, E. Hopper-Borge, M. G. Belinsky, I. Shchaveleva, E. Kotova, and G. D. Kruh Characterization of the Transport Properties of Human Multidrug Resistance Protein 7 (MRP7, ABCC10) Mol. Pharmacol., February 1, 2003; 63(2): 351 - 358. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Oleschuk, R. G. Deeley, and S. P. C. Cole Substitution of Trp1242 of TM17 alters substrate specificity of human multidrug resistance protein 3 Am J Physiol Gastrointest Liver Physiol, February 1, 2003; 284(2): G280 - G289. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-F. Fu, J. N. Scarsdale, G. Kazanina, V. Schirch, and H. T. Wright Location of the Pteroylpolyglutamate-binding Site on Rabbit Cytosolic Serine Hydroxymethyltransferase J. Biol. Chem., January 17, 2003; 278(4): 2645 - 2653. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Koike, C. J. Oleschuk, A. Haimeur, S. L. Olsen, R. G. Deeley, and S. P. C. Cole Multiple Membrane-associated Tryptophan Residues Contribute to the Transport Activity and Substrate Specificity of the Human Multidrug Resistance Protein, MRP1 J. Biol. Chem., December 13, 2002; 277(51): 49495 - 49503. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Haimeur, R. G. Deeley, and S. P. C. Cole Charged Amino Acids in the Sixth Transmembrane Helix of Multidrug Resistance Protein 1 (MRP1/ABCC1) Are Critical Determinants of Transport Activity J. Biol. Chem., October 25, 2002; 277(44): 41326 - 41333. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Volk, K. M. Farley, Y. Wu, F. Li, R. W. Robey, and E. Schneider Overexpression of Wild-Type Breast Cancer Resistance Protein Mediates Methotrexate Resistance Cancer Res., September 1, 2002; 62(17): 5035 - 5040. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-S. Chen, K. Lee, S. Walther, R. B. Raftogianis, M. Kuwano, H. Zeng, and G. D. Kruh Analysis of Methotrexate and Folate Transport by Multidrug Resistance Protein 4 (ABCC4): MRP4 Is a Component of the Methotrexate Efflux System Cancer Res., June 1, 2002; 62(11): 3144 - 3150. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |